Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have earned an average recommendation of “Moderate Buy” from the fourteen analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $92.43.

A number of equities analysts have recently issued reports on RARE shares. Piper Sandler upped their price target on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, January 13th. TD Cowen upped their target price on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Royal Bank of Canada reissued an “outperform” rating and issued a $77.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, November 6th. Wells Fargo & Company upped their price objective on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a report on Friday, December 20th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $121.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 12th.

Insider Activity

In related news, CEO Emil D. Kakkis sold 11,727 shares of the business’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $42.23, for a total value of $495,231.21. Following the completion of the transaction, the chief executive officer now directly owns 2,183,985 shares in the company, valued at $92,229,686.55. The trade was a 0.53 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 5.80% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 259.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 493 shares in the last quarter. True Wealth Design LLC purchased a new position in Ultragenyx Pharmaceutical during the third quarter worth approximately $43,000. Human Investing LLC acquired a new stake in Ultragenyx Pharmaceutical in the fourth quarter valued at approximately $42,000. Values First Advisors Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at approximately $56,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $83,000. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE stock opened at $45.35 on Monday. The company has a market capitalization of $4.19 billion, a P/E ratio of -7.01 and a beta of 0.60. The company’s 50-day simple moving average is $44.00 and its two-hundred day simple moving average is $49.65. Ultragenyx Pharmaceutical has a one year low of $37.02 and a one year high of $60.37.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.